W e read with great interest the article by Chesson et al., 1 which illustrated the possible economic losses that may be averted by slowing the emergence of ceftriaxone-resistant Neisseria gonorrhoeae infections. As the threat of untreatable N. gonorrhoeae infection increases, 2 rapid molecular assays for the timely prediction of antimicrobial susceptibility are increasingly being used to target antimicrobial therapy. 3 A recent modeling study demonstrated the theoretical delay in the emergence of multidrugresistant N. gonorrhoeae with the use of such rapid molecular assays. 4 The University of California, Los Angeles Health System has implemented a rapid molecular assay for the determination of mutation in the gyrase A (gyrA) gene of N. gonorrhoeae. 5, 6 The absence of mutation in that gene has been shown to reliably predict susceptibility to ciprofloxacin. 7 As suggested by the article by Chesson et al., the use of ciprofloxacin may spare ceftriaxone and thus reduce the emergence of ceftriaxone-resistant N. gonorrhoeae infections. 8 Ciprofloxacin has been shown to be greater than 99% effective among infections with phenotypic susceptibility 9 ; however, one concern regarding the current utility of ciprofloxacin in the treatment of N. gonorrhoeae infections is that there have been no studies evaluating patient outcomes among those with wild-type (nonmutated) gyrA genotype N. gonorrhoeae infection. We have collected outcome data from participants with wildtype N. gonorrhoeae infections treated with ciprofloxacin at the University of California, Los Angeles Health System. We completed a retrospective review of 25 patient records between June 2016 and September 2017, with a repeat N. gonorrhoeae test performed between 7 and 90 days after single dose ciprofloxacin 500 mg oral treatment of the initial infection. Of those 25 participants, 100% (95% confidence interval, 83%-100%) had a negative test-of-cure result. The anatomic sites of infection included rectal (n = 7), pharyngeal (n = 7), urethral (n = 7), and unspecified genital swabs (n = 4). There was no difference in repeat test results by time to repeat test 7 to 21 days (100%) versus 22 to 90 days (100%) (P > 0.1).
Those preliminary results provide promising evidence of the efficacy of ciprofloxacin for the treatment of wild-type gyrA genotype N. gonorrhoeae infections. There are additional costs to gyrA genotyping and genotype-based therapy compared with recommended empiric 2-drug therapy with ceftriaxone and azithromycin 10 ; however, in the light of the potential costs incurred by the emergence of ceftriaxone-resistant infections as suggested by Chesson et al., we advocate for further implementation of the gyrA genotypic assay in other health systems for the promotion of targeted N. gonorrhoeae therapy.
